Blood test after CAR-T could spot returning cancer weeks earlier
NCT ID NCT05675982
First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 20 times
Summary
This study looks at whether a blood test can quickly detect leftover cancer DNA in people treated with CAR-T cells for diffuse large B-cell lymphoma. About 40 adults will give a blood sample a week after their CAR-T infusion, and researchers aim to report results within three weeks. The goal is to see if early detection of remaining cancer can help doctors offer additional treatment sooner.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Henri Becquerel
Rouen, France
Conditions
Explore the condition pages connected to this study.